MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab...
-
Upload
elwin-melton -
Category
Documents
-
view
219 -
download
2
Transcript of MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab...
![Page 1: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/1.jpg)
MAX: International multi-centre randomised phase II/III study of
capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC):
Final safety analysis of an AGITG trial.
T Price, V. Gebski, G. van Hazel, B. Robinson, A. Broad, V. Ganju, D. Cunningham, K. Wilson, V. Tunney, N. Tebbutt : on behalf of the Australasian GI Trials Group
![Page 2: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/2.jpg)
Colorectal Cancer
2nd most common cause of cancer death
Increasing age is a major risk factor for colorectal cancer
Older patients have greater chance of co-morbidities
Metastatic colorectal cancer is incurable
Palliative chemotherapy has an established role for patients with mCRC with prolonged survival and improved QoL
![Page 3: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/3.jpg)
Current metastatic colorectal cancer treatments
Older patients usually have monotherapy such as capecitabine monotherapy
Younger patient usually have combination therapy such as FOLFOX or FOLFIRI
![Page 4: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/4.jpg)
Background/Rationale
Capecitabine & bevacizumab+/-MMC
Good activity with minimal toxicity
Suitable for broad range of population
Young & fit
Older & less fit
Less data available on older less fit patients
![Page 5: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/5.jpg)
Study ObjectivesStage One – Phase II
Primary objective: Relative toxicity of the three treatment arms
Secondary objective : Tumour response rate
Stage Two – Phase III
Primary objective : Comparison of progression free survival
Secondary objectives Treatment related toxicity Tumour response rates Overall survival Disease-related symptoms and Quality of Life Cost effectiveness of bevacizumab
![Page 6: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/6.jpg)
Inclusion and Exclusion Criteria
Histological diagnosis of colorectal cancerMetastatic disease that is not resectableAny patient for whom the investigator considers capecitabine monotherapy appropriateECOG performance status 0, 1 or 2. Patients with PS2 should have serum albumin >30 g/L Adequate bone marrow, renal and hepatic function No major surgical procedure within the last 28 daysNo other malignant disease Written informed consent
![Page 7: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/7.jpg)
Inclusion and Exclusion Criteria
No prior chemotherapy except for adjuvant chemotherapy given in association with
(ii) complete resection of primary colon or rectal cancer provided there is no clinical, radiological or biochemical evidence of relapse for at least 6 months after completion of adjuvant treatment and/or
(ii) complete resection of limited colorectal metastases to liver and/or lung provided there is no clinical, radiological or biochemical evidence of relapse for at least 6 months after completion of adjuvant treatment
![Page 8: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/8.jpg)
Study Schema
RANDOMISE
STRATIFY
Age(>65y vs <65y)
PS (0,1 vs 2)
Capecitabine dose (2000 vs 2500 mg/m2/d)
Institution
ARM C:CAPECITABINE + BEVACIZUMAB+ MITOMYCIN C
ARM B: CAPECITABINE + BEVACIZUMAB
ARM A: CAPECITABINE
PROGRESSION FREE
SURVIVAL
TREATMENT PRIMARY ENDPOINT
![Page 9: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/9.jpg)
Recruitment
First patient recruited on 14th July 2005Last patient recruited on 10th July 2007
471 patients were recruited from 43 sites.38 sites in Australia2 sites in New Zealand3 sites in the United Kingdom
13 patients were ineligible (10 < 6mths post adjuvant chemotherapy, 2 prior carcinoma, 1 hypoalbuminemia/PS 2)3 patients were randomised but did not commence study treatment
![Page 10: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/10.jpg)
Baseline Demographics
Cap (n=156)
Cap/Bev (n=157)Cap/Bev/
MMC (n=158)
Median age (years, range) 69 (37-86) 67 (32-85) 67 (33-84)
Male/Female % 63/37 65/35 60/40PS 0-1 (%) 96 92 93Cap dose 2000mg/m2/day (%)
66 67 67
Liver metastases (%) 72 75 77Nodal metastases (%) 44 50 44Pulmonary metastases (%) 39 40 39Peritoneal metastases (%) 21 13 19Prior adjuvant treatment (%) 22 27 16
![Page 11: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/11.jpg)
Cap (n=156) Cap/Bev (n=157) Cap/Bev/MMC (n=158)
Diarrhoea 62 (11) 62 (15) 68 (14)
Hand-foot syndrome 65 (15) 75 (25) 78 (26)
Stomatitis 27 (3) 47 (2) 54 (4)
Vomiting 29 (5) 34 (5) 35 (3)
Nausea 52 (5) 64 (5) 68 (5)
Fatigue 76 (9) 79 (10) 84 (13)
Febrile neutropenia (2) (2) (3)
Infection with neutropenia
24 (5) 33 (9) 32 (9)
Neutropenia 9 (1) 10 (0) 20 (2)
Thrombocytopenia 9 (0) 13 (0) 42 (3)
Transaminitis 28 (1) 32 (3) 35 (1)
Bilirubin (2) (1) (1)
General toxicities
% all grades (grade 3/4/5)
![Page 12: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/12.jpg)
Events of special interestCap (n=156) Cap/Bev (n=157) Cap/Bev/MMC
(n=158)
Proteinuria 13 (<1) 31 (3) 43 (7)
Hypertension 13 (<1%) 25 (3) 23 (5)
VTE (8) (8) (10)
Cardiac ischemia 1 (0) 4 (3) 3 (1)
CNS ischemia (0) (0) (3)
Epistaxis 4 (0) 29 (0) 26 (0)
Haemorrhage (3) (1) (4)
GI perforation (n=)
1 3 0
Haemolytic uraemic syndrome (n=)
0 0 2
% all grades (grade 3/4/5)
![Page 13: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/13.jpg)
Conclusion
Treatment well tolerated in all 3 arms.
Addition of Bev or Bev and MMC to Cap was associated with little additional grade 3/4 toxicity, apart from higher rates of grade 3 HFS in Arms B and C.
Acceptable rates of grade 3/4 HT, VTE, haemorrhage & perforation was in the Bev arms.
![Page 14: MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649f455503460f94c66af0/html5/thumbnails/14.jpg)
Contact
Dr Tim PriceSenior Consulting Medical OncologistOncology Dept
Queen Elizabeth HospitalWoodville Rd
Woodville South SA 5011 Tel: +61 8 8222 6000
Fax: +61 8222 7054